Tyrrell et al., 2014 - Google Patents
Gaining the upper hand on pulmonary drug deliveryTyrrell et al., 2014
View HTML- Document ID
- 5380669092230791277
- Author
- Tyrrell J
- Tarran R
- Publication year
- Publication venue
- Journal of pharmacovigilance
External Links
Snippet
Abstract Asthma, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF) are all pulmonary diseases which are characterized by chronic inflammation and an increase in mucus production. Excess mucus in the airways correlates with pathophysiology …
- 239000003814 drug 0 title abstract description 56
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Garcia-Contreras et al. | Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model | |
| King et al. | Aspergillus infections in cystic fibrosis | |
| Patil et al. | A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis | |
| Grasemann et al. | Inhalation of Moli1901 in patients with cystic fibrosis | |
| Rossi et al. | Erythrocyte‐mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease | |
| Flume et al. | State of progress in treating cystic fibrosis respiratory disease | |
| Rottner et al. | Mechanisms of the noxious inflammatory cycle in cystic fibrosis | |
| Paleari et al. | Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood | |
| RU2389477C2 (en) | Methods of treating endobronchial diseases | |
| JP6087862B2 (en) | Method for treating pulmonary disease with liposomal amikacin formulation | |
| Alothman et al. | Bronchial constriction and inhaled colistin in cystic fibrosis | |
| US9987227B2 (en) | Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile | |
| Middleton et al. | Effect of amiloride and saline on nasal mucociliary clearance and potential difference in cystic fibrosis and normal subjects. | |
| ES2775606T3 (en) | Fluticasone furoate in the treatment of COPD | |
| Tyrrell et al. | Gaining the upper hand on pulmonary drug delivery | |
| Wigenstam et al. | Corticosteroid treatment inhibits airway hyperresponsiveness and lung injury in a murine model of chemical-induced airway inflammation | |
| Schmitt-Grohé et al. | Leukotriene receptor antagonists in children with cystic fibrosis lung disease: anti-inflammatory and clinical effects | |
| US20180243213A1 (en) | Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport | |
| US20190231884A1 (en) | Synthetic pulmonary surfactant composition for treating lung conditions | |
| WO2012017406A1 (en) | Exogenous pulmonary surfactant preparation comprising a phospholipid and an adjuvans | |
| Kulkarni et al. | Liposomal Drug Delivery: Therapeutic Applications in Chronic Respiratory Diseases | |
| Fayon | CF-Emerging therapies: Modulation inflammation | |
| CN101897719B (en) | Medical composite used for treating smoke inhalation lung injury | |
| UA119558C2 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| Harini et al. | A Review On Resealed Erythrocytes |